ProQR Therapeutics N.V.’s (NASDAQ:PRQR) Price Is Out Of Tune With Revenues
You may think that with a price-to-sales (or “P/S”) ratio of 13.3x ProQR Therapeutics N.V. (NASDAQ:PRQR) is a stock to potentially avoid, seeing as almost half of all the Biotechs companies in the United States have P/S ratios under 10.4x and even P/S lower than 4x aren’t out of the ordinary. Although, it’s not wise to just take the P/S at face value as there may be an explanation why it’s as high as it is.
Check out our latest analysis for ProQR Therapeutics
What Does ProQR Therapeutics’ Recent Performance Look Like?
ProQR Therapeutics could be doing…
